Company intelligence / Profile preview

Santos Biotech

Oxford, Florida, United States

Ownership: Private
Development stage: Other

Overview

Santos Biotech is a pre-clinical stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer and inflammatory diseases. The company's lead candidate, SBT-100, is a potent and selective inhibitor of the STAT3 protein, which plays a critical role in tumor growth, survival, and immune evasion. Santos Biotech is currently advancing SBT-100 through IND-enabling studies for indications including pancreatic cancer and glioblastoma. Additionally, the company is exploring the potential of its STAT3 inhibitors in dermatological conditions such as psoriasis. The firm aims to address high unmet medical needs by targeting pathways that are constitutively active in many human cancers.

Therapeutic areas: OncologyDermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Santos Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Santos Biotech.

Explore the full profile